Trials / Completed
CompletedNCT01243489
Compliance: Role Emerges for Success in Chronic Myelogenous Leukaemia (CML): Evaluation aND Optimisation
CRESCENDO (Compliance: Role Emerges for Success in CML: Evaluation aND Optimisation): A Prospective, Multi-center, Phase IV Study to Assess the Compliance in Patients With Philadelphia Chromosome-positive (Ph+) and/or BCR-ABL Positive Chronic Myelogenous Leukaemia (CML) Under Long-term Imatinib Therapy
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 104 (actual)
- Sponsor
- Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study on patient's compliance in clinical workaday life aims to assess and to improve CML treatment in Germany by means of adherence supporting measures and to increase adherence awareness by physicians and patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | compliance supporting measures | Patients will be treated for a total of 12 months, 6 months without and 6 months with compliance supporting measures. Patient can choose between an information service "Leben mit CML" or the use of a daily diary |
Timeline
- Start date
- 2010-10-01
- Primary completion
- 2013-06-01
- Completion
- 2018-06-01
- First posted
- 2010-11-18
- Last updated
- 2019-12-20
Locations
23 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT01243489. Inclusion in this directory is not an endorsement.